Abstract:In this work, structure‐based computational design strategies, mainly structure‐based pharmacophore modelling, virtual screening, molecular docking, ADMET prediction, and molecular dynamic (MD) simulations, along with their validation, are performed for the design of novel thiadiazole derivatives as hDHODH inhibitors. Designed compounds 8d and 2d demonstrated good potential for their future development as selective hDHODH inhibitors and anticancer agents. This study involves the design of novel thiadiazole derivatives as hDHODH inhibitors using various structure‐based approaches such as pharmacophore modelling, high‐throughput virtual screening (HTVS), prediction of ADMET parameters, docking and molecular dynamics (MD) studies. We used the validated co‐crystal structure of hDHODH to create the six‐feature pharmacophore model ADHRRR, which was validated by the Güner‐Henry scoring (GH score=0.81) approach, enrichment calculations (enrichment factor=51), area under the curve (0.93), receiving operating characteristic (ROC) curve (0.89), and ROC′s Boltzmann‐enhanced discrimination, known as BEDROC (α=8) (0.859), (α=20) (0.828), (α=160) (0.912). Pharmacophore model as a 3D search query was used for the screening of zinc database followed by docking investigations and energy calculation (Prime/MMGBSA). For the design of novel compounds, we selected the thiadiazole moiety as the central scaffold and various functional groups based on pharmacophoric characters and binding interactions. In docking study, designed compounds showed favourable interactions with Gln47 and Arg136 at the active site of the hDHODH enzyme, and optimal drug likeness properties for ADMET prediction study. Stability of enzyme‐ligand complex was validated by MD simulation study with RMSD, RMSF and RoG calculations. These findings suggested that novel thiadiazoles are potential candidates as hDHODH inhibitors and anticancer agents.

Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives

DHODH and cancer: promising prospects to be explored

Advances in DHODH: A Target for Treating Tumors

Structure-based design of potent human dihydroorotate dehydrogenase inhibitors as anticancer agents

Progress and Study of Dihydrofolate Reductase Inhibitors in Tumor Therapy

A Novel Series of Human Dihydroorotate Dehydrogenase Inhibitors Discovered by in Vitro Screening: Inhibition Activity and Crystallographic Binding Mode

Discovery of Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on a Benzophenone Scaffold

Targeting ribonucleotide reductase for cancer therapy.

Design, Synthesis, and Biological Evaluation of a Novel Series of Teriflunomide Derivatives as Potent Human Dihydroorotate Dehydrogenase Inhibitors for Malignancy Treatment

Discovery of Nanomolar Inhibitors for Human Dihydroorotate Dehydrogenase Using Structure-Based Drug Discovery Methods

Discovery a Series of Novel Inhibitors of Human Dihydroorotate Dehydrogenase: Biological Activity Evaluation and Molecular Docking.

Biological Evaluation of Quinoline Derivatives As Inhibitors of Human Dihydroorotate Dehydrogenase

Structural Optimization and Structure–Activity Relationship of 4-Thiazolidinone Derivatives As Novel Inhibitors of Human Dihydroorotate Dehydrogenase

Recent advances in pyruvate dehydrogenase kinase inhibitors: Structures, inhibitory mechanisms and biological activities

Hypusination-induced DHPS/eIF5A pathway as a new therapeutic strategy for human diseases: A mechanistic review and structural classification of DHPS inhibitors

[Design, Synthesis and Structure-Activity Relationship Studies of Human Dihydroorotate Dehydrogenase Inhibitors].

Discovery and Optimization of Novel <i>h</i>DHODH Inhibitors for the Treatment of Inflammatory Bowel Disease

Discovery of a Novel Series of Hdhodh Inhibitors with Anti-Pulmonary Fibrotic Activities.

Discovery of Thiadiazoles as Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors by Combined Structure‐Based Modelling Methods

3093 – DHODH INHIBITION SYNERGIZES WITH DNA-DEMETHYLATING AGENTS IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES

Exploring Marine-Derived Ascochlorins as Novel Human Dihydroorotate Dehydrogenase Inhibitors for Treatment of Triple-Negative Breast Cancer